“Isoprex Slashes Pain in 5 Days – Naturally!” “Walking without a Cane!” “Clinically Proven!” “Relieves painful swelling in 100% of even the worst cases.” These claims are false or misleading, according to the FTC’s complaint against Isoprex’s distributor, Renaissance Health Publishing, Inc.
Maybe you’ve seen the ads. Renaissance advertises Isoprex primarily through mailings targeting older adults. The ads claim that Isoprex provides relief for all types of pain, helps rebuild joints, and reduces inflammation. The ads also promote Isoprex as a natural pain reliever that’s superior to non-steroid anti-inflammatory drugs like aspirin or ibuprofen. But the FTC’s complaint alleges that these claims are false or misleading and that the company can’t back them up with clinical proof.
What’s more, the FTC says that the endorsements of Isoprex are deceptive. Some of the people who claim that Isoprex helped them were actually company employees or relatives of employees. Others got money or supplies in exchange for their glowing testimonials.
How can you better evaluate health claims, like those made about Isoprex?
- Be skeptical about who is writing product reviews. Look for well-known sites that review products rather than sites that sell the products.
- Talk to your health care professional. Before using any new supplement, ask your doctor about its effectiveness, as well as how it might interact with your medications. Remember that dietary supplements are not regulated like drugs – the FDA does not evaluate or review supplements for safety or effectiveness.
- Consult reliable sources of health information. For up-to-date information on arthritis treatments and alternative therapies, call the Arthritis Foundation at 1-800-283-7800 or visit arthritis.org. For other conditions, consult the Centers for Disease Control and Prevention at cdc.gov.
The purpose of this blog and its comments section is to inform readers about Federal Trade Commission activity, and share information to help them avoid, report, and recover from fraud, scams, and bad business practices. Your thoughts, ideas, and concerns are welcome, and we encourage comments. But keep in mind, this is a moderated blog. We review all comments before they are posted, and we won’t post comments that don’t comply with our commenting policy. We expect commenters to treat each other and the blog writers with respect.
- We won’t post off-topic comments, repeated identical comments, or comments that include sales pitches or promotions.
- We won’t post comments that include vulgar messages, personal attacks by name, or offensive terms that target specific people or groups.
- We won’t post threats, defamatory statements, or suggestions or encouragement of illegal activity.
- We won’t post comments that include personal information, like Social Security numbers, account numbers, home addresses, and email addresses. To file a detailed report about a scam, go to ReportFraud.ftc.gov.
We don't edit comments to remove objectionable content, so please ensure that your comment contains none of the above. The comments posted on this blog become part of the public domain. To protect your privacy and the privacy of other people, please do not include personal information. Opinions in comments that appear in this blog belong to the individuals who expressed them. They do not belong to or represent views of the Federal Trade Commission.
In reply to So, is this the first step by Ronnie Robbie
The press release has information about the FTC settlement that bars the company from continuing to make its unproven claims. The order also would impose a judgment of $3.93 million, which is partially suspended due to an inability to pay, after the defendants pay $100,000. The FTC may use those funds to pay refunds to consumers harmed by the defendants’ allegedly misleading advertising.